USOO9050343B2 (12) United States Patent (10) Patent No.: US 9,050,343 B2 Peters et al. (45) Date of Patent: Jun. 9, 2015 (54) COMBINATION OF PIMAVANSERIN AND 4,332,804 A 6, 1982 Clark RSPERIDONE FOR THE TREATMENT OF 13. A 9. at: al PSYCHOSIS 4,367,232 A 1/1983 Boix-Igleasias et al. (71) Applicants: Perry Peters, San Diego, CA (US); 3. A SME,R al David Furlano, San Diego, CA (US); 5,214,055 A 5/1993 Peglion et al. Daun Bahr, San Diego, CA (US); 5,216,165 A 6/1993 Mobilio et al. Daniel Van Kammen, San Diego, CA 5,461,066 A 10, 1995 Gericke et al. (US) 5,595,872 A 1/1997 Wetterau, II et al. 5,621,010 A 4/1997 Sueda et al. (72) Inventors: Perry Peters, San Diego, CA (US); 5,707,798 A 1/1998 Brann David Furlano, San Diego, CA (US); 3. A E. Shet al. Daun Bahr, San Diego, CA (US); 5,869,488 A 2, 1999 Shue et al. Daniel Van Kammen, San Diego, CA 5,877,173 A 3/1999 Olney et al. (US); Mark Brann, Rye, NH (US) 5,912,132 A 6/1999 Brann 5,955,281 A 9, 1999 Brann (73) Assignee: ACADIA Pharmaceuticals Inc., San 6,107,324 A 8, 2000 Behan et al. Diego, CA (US) 6,140,509 A 10/2000 Behan et al. 6,150,393 A 11/2000 Behan et al. (*) Notice: Subject to any disclaimer, the term of this E. R f29: y s al patent is extended or adjusted under 35 6,486,153- B1 1 1/2002 Castrooyes Pineiroet al. et al. U.S.C. 154(b) by 89 days. 6,670,137 B2 12/2003 VanMechelen et al. 6,756,393 B2 6/2004 Andersson et al. (21) Appl. No.: 13/754,769 6,815,458 B2 11/2004 Andersson et al. 6,911,452 B2 6/2005 Schlienger (22) Filed: Jan. 30, 2013 7,022,698 B2 4/2006 Hamied et al. 7,041,667 B1 5/2006 Armour et al. (65) Prior Publication Data 7,115,634 B2 10/2006 Thurieau et al. 7,253,186 B2 8/2007 Andersson et al. US 2013/0143901 A1 Jun. 6, 2013 7,601,740 B2 10/2009 Weiner et al. (Continued) Related U.S. Application Data (62) Division of application No. 12/051,807, filed on Mar. FOREIGN PATENT DOCUMENTS 19, 2008, now abandoned. CA 984843 3, 1976 (60) Provisional application No. 60/895,735, filed on Mar. EP 0 005 3.18 11, 1979 19, 2007, provisional application No. 60/908,921, (Continued) filed on Mar. 29, 2007, provisional application No. 61/012,771, filed on Dec. 10, 2007, provisional OTHER PUBLICATIONS application No. 61/026,092, filed on Feb. 4, 2008. Poewe (Movement Disorders vol. 18, Suppl. 6, 2003, pp.S80-S87).* (51) Int. Cl. (Continued) A 6LX3/59 (2006.01) A6 IK3I/4468 (2006.01) 3. f 3:08: Primary Examiner — David J Blanchard A6 IK3 L/455 (2006.01) Assistant Examiner — Garen Gotfredson A 6LX3/553 (2006.01) (74) Attorney, Agent, or Firm — Jones Day A6 IK3I/554 (2006.01) (52) U.S. Cl. CPC ............... A6 IK3I/519 (2013.01); A61 K3I/00 (57) ABSTRACT (2013.01); A61K3I/4468 (2013.01); A61 K 3 1/4515 (2013.01); A61 K3I/5513 (2013.01); Combinations of 5-HT2A inverse agonists or antagonists A61 K3I/554 (2013.01) Such as pimavanserin with antipsychotics Such as risperidone (58) Field of Classification Search are shown to induce a rapid onset of antipsychotic action and None increase the number of responders when compared to therapy See application file for complete search history. with the antipsychotic alone. These effects can be achieved at a low dose of the antipsychotic, thereby reducing the inci (56) References Cited dence of side effects. The combinations are also effective at decreases the incidence of weight gain and increased glucose U.S. PATENT DOCUMENTS or prolactin levels caused by the antipsychotic. 3,983,234 A 9/1976 Sayers 4,138.492. A 2f1979 Noverola et al. 4.255.432 A 3/1981 Kluge et al. 6 Claims, 42 Drawing Sheets US 9,050,343 B2 Page 2 (56) References Cited WO WO 2005/053796 6, 2005 WO WO 2005/063254 7/2005 U.S. PATENT DOCUMENTS WO WO 2005/112927 12/2005 WO WO 2005.112927 A1 * 12/2005 7,659,285 B2 2/2010 Weiner et al. WO WO 2006/036874 4/2006 7,732.462 B2 6/2010 Weiner et al. WO WO 2006/037043 4/2006 7.994, 193 B2 8/2011 Weiner et al. WO WO 2006,104826 10, 2006 8.227.487 B2 7/2012 Weiner et al. WO WO 2004/039322 5/2007 8,377,959 B2 2/2013 Weiner et al. WO WO2007.1338O2 11, 2007 2002/0156068 A1 10, 2002 Behan et al. 2002fO165225 A1 11/2002 Kankan et al. OTHER PUBLICATIONS 2004.0006081 A1 1/2004 Burrows et al. 2004/0106600 A1 6/2004 Andersson et al. Adam, et al. 1989. Effects of repeated ritanserin on middle-aged poor 2004/021381.6 A1 10, 2004 Weiner et al. sleepers. Psychopharmacology, 99:219-221. 2005, OO14757 A1 1/2005 Andersson et al. Adell, et al. 2005. Strategies for producing faster acting antidepres 2005, 0148018 A1 7, 2005 Weiner et al. sants. Drug Discovery Today, 10(8):578-585. 2005/0244862 AI 1 1/2005 Brann Akin, et al. 2004. Decreased serotonin 5-HT, receptor-stimulated 2005/0256.108 Al 11/2005 Schlienger phosphoinositide signaling in fibroblasts from melancholic 28393. E. A. 39 Wine et al depressed patients. Neuropsychopharmacology, 29:2081-2087. 2005/0288328 A1 12, 2005 WE I. Alvisi, N. 1892. Sulla formazione di derivati pirazolici dalle 2006/0094758 A1 5/2006 Andersson et al dicloridrine e dalla tribromidrina della glicerina ordinaria, Gazz. 2006/0106063 A1 5/2006 Thhygesen et al. Chen. Ital. 22:158-168. 2006/011 1399 A1 5/2006 Thhygesen et al. Antilla, et al. 2001. Copper-catalyzed coupling of arylboronic acids 2006/O194778 A1 8/2006 Andersson et al. and amines. Organic Letters, 3(13):2077-2079. 2006, O194834 A1 8/2006 Andersson et al. Antilla, et al. 2002. The copper-catalyzed N-arylation of indoles. J. 2006/0199794 A1 9/2006 Schlienger Am. Chem. Soc., 124:1 1684-1 1688. 2006, O1998.18 A1 9/2006 Andersson et al. Antunes, et al., 2012. The novel object recognition memory: 2006, O199842 A1 9, 2006 Weiner et al. neurobiology, test procedure, and its modifications. Cogn Process 2006/0204486 A1 9/2006 Pyke et al. 13:93-110. 2006/0205710 A1 9/2006 Schlienger et al. Archibald, et al., 1974 “1,4-Bis-(2-indol-3-ylethyl)piperdines' J. 2006/0205722 A1 9/2006 Andersson et al. Medicinal Chemistry, 17(7):745-747. 2006/0205780 A1 9/2006 Thygesen et al. Archibald, et al., 1974 "Benzamidopiperdines. 2. Heterocyclic Com 2006/0205781 A1 9, 2006 Thvgesenyg et al. pounds Related to Indoramin' J. Medicinal Chemistry, 17(7):736 2006/0264465 A1 11/2006 Weiner et al. 739. 2006/0264466 A1 11/2006 Weiner et al. Archibald, et al., 1974 "Benzamidopiperdines. 3. Heterocyclic Com 2006/028661.0 A1 12, 2006 Brann pounds Related to Indoramin' J. Medicinal Chemistry, 17(7):739 2006,029.2606 A1 12, 2006 Brann 744. 2009.0053329 A1 2/2009 Peters et al. Artico, et al. 1992. Aromatic hydrazides as specific inhibitors of bovine serum amine oxidase. Eur: J. Med. Chem., 27:219-228. FOREIGN PATENT DOCUMENTS Bakshi, et al. 1994. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. The Journal of EP O 061333 9, 1982 Pharmacology and Experimental Therapeutics, 271 (2):787-794. EP O 379 441 7, 1990 Barchas, J. 1973. Serotonin and Behavior. New York: Academic EP O 548 O15 6, 1993 Press. EP O 260 070 8, 1993 Barnes, et al. 1999. A review of central 5-HT receptors and their FREP O28O2206 625 507 11,6, 20011994 function.inction. Neuropharmacology,N. h l 38:1083-115238:1U85-1154. HU 1573.25 3, 1998 Barr, et al. 1997. Agonist-independent activation of G by the JP 51052176 5, 1976 5-hydroxytryptamine receptor coexpressed in Spodoptera JP 52O8517 7/1977 frugiperda cells. The Journal of Biological Chemistry, WO WO 94,27967 12/1994 272(52):32979-32987. WO WO97,081.66 3, 1997 Bassus, et al. 1974. Psychotropes potentiels. X. Synthese de WO WO97,11940 4f1997 butyrophenones a cycle piperidine-spiro-tetrahydrooxazinone WO WO97/38665 10, 1997 douees d'activite neuroleptique. Eur: J. Med. Chem.–Chimica WO WO97,38984 10, 1997 Therapeutica, 9(4):416–423. WO WO98, 11128 3, 1998 Bennett, et al. 1993. Suppression of dyskinesias in advanced W. W. SE 38 Parkinson's disease. II. Increasing daily clozapine doses Suppress WO WO98,50534 11, 1998 dyskinesias and improve parkinsonism symptoms. Neurology, 43:1551-1555. W. W. 8587. 1992 Bhatia, et al. 1996. 5-Lipoxygenase inhibitors: Synthesis and struc WO WOOO,56335 9, 2000 ture-activity relationships of a series of 1-Aryl-2H4H-tetrahydro-1 WO WOOO. 59497 10, 2000 2,4-triazin-3-ones. J. Med. Chem. 39:3938-3950. WO WOOOf 69810 11, 2000 Biagi, et al. 1988. 1,2,3-Triazoles: Structural changes on two effec WO WOO1/44.191 6, 2001 tive inhibitors of the prostaglandin synthesis in vitro. Farmaco Ed. WO WOO1? 66521 9, 2001 Sci., 43:597-612. WO WOO1f87839 11, 2001 Bibbiani, et al. 2001. Serotonin 5-HT1A agonist improves motor W. w8%2: d29: complications in rodent and primate parkinsonian models.